CMI PRESS RELEASE

Summary:

Metabolic testing involves assessment of health and wellbeing of an individual. Metabolic testing equipment are used to screen organ functions and disease conditions such as liver diseases, diabetes, kidney diseases, and cardiovascular diseases.

The global Metabolic Testing Market size was valued at US$ 451.5 Mn in 2018.

 Regulatory Scenario

Medical devices are classified into three categories: Class 1, Class 2, and Class 3. This classification is risk-based, where risk posed by the device to the patient represents category of the medical device. For instance, class 1 includes devices with lowest risk, class 2 includes medium risks, whereas class 3 includes devices with the highest risk.

The U.S. Food and Drug Administration (FDA) classifies metabolic testing devices into class II of medical device classification system. According to the U.S. FDA, if a device is classified into either class II (Special Controls) or class III, it may be subject to additional controls. The U.S. FDA classifies a device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.

 Request for the Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/1652

Market Opportunity

Technological advancements in healthcare IT sector has enabled effective integration of complex healthcare and IT systems. Technologies such as cloud computing, data analytics, big data, and patient monitoring are majorly being used in healthcare.

This trend (connected health) has affected metabolic testing devices as well, as manufacturers are introducing portable/wearable devices with advanced features such as Bluetooth connectivity, inbuilt ECG monitors, fitness trackers, and other such multiple features.

However, metabolic testing is still not a necessity beyond situational requirement and metabolic testing is yet to reach its full potential. In such scenario, connected and portable metabolic testing devices may play a major role in enhancing the accessibility of metabolic testing. Examples of such devices include, K5 Wearable Metabolic System (manufactured by Cosmed srl), InBody BAND 2 (manufactured by InBody Co.,Ltd.), and VO2 Master Pro (manufactured by VO2 Master).

 Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1652

Market Drivers

Increasing approval and launch of new products, high prevalence of lifestyle diseases, and better reimbursement policies is expected to be major factors drastically driving metabolic testing market growth. For instance, manufacturers have introduced products such as Quark CPET (Cosmed srl) with multiple configurations such as ECG testing and nutritional assessment and products such as ReeVue (Korr Medical Technologies Inc.) with mixing chamber technology, self-calibration, and reimbursement facility.

Prevalence of lifestyle diseases is high in key region. Lifestyle diseases can lead to metabolic diseases which in turn is expected to rise demands for metabolic testing devices and drive metabolic testing market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), over one third of the adults in the U.S. had obesity in 2014.

 Market Restraint

High cost of metabolic testing devices, preference to these devices under limited circumstances (sports performance testing and others), low penetration in emerging economies in regions such as Latin America, Asia Pacific, and Middle East are factors that are expected to restrain growth of the market.

 Key players operating in the Metabolic Testing Market include,

Cosmed srl, Vyaire Medical, Inc., Geratherm Medical AG, MGC Diagnostics Corporation, Cortex Biophysik GmbH, General Electric Company, Microlife Medical Home Solutions, Inc., OSI Systems, Inc., AEI Technologies, Inc., and Korr Medical Technologies, Inc.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Personal mobility devices play a major role in advanced healthcare, as it aid in mobility of the disabled people and enhance the independent living. The devices are of great use for disabled athletes for participation in sports events such as Paralympic World Cup and others.

The global Personal Mobility Devices Market size was valued at US$ 7,818.5 million in 2017.

Figure 1. Global Personal Mobility Devices Market Value (US$ Mn), by Region, 2017

Market Drivers:

Increasing disability cases is expected to drive the global personal mobility devices market growth. According to the World Population Prospects in 2017, global population aged over 60 years was 962 million, which is expected to reach around 2.1 billion by 2050. Globally, population aged 60 years and above is increasing faster than all younger age groups.

Moreover, increasing product development and focus on addressing issues faced by wheelchair users, by manufacturers, is expected to propel growth of the market over the forecast period. For instance, Sunrise Medical (US) LLC launched advanced power wheelchair in 2016. The wheelchair, designed by Sunrise Medical (US) LLC, is assembled with a suspension and has advanced seating system, which supports complex seating and positioning needs. Furthermore, this chair has electronic features and user control.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1662

Market Restraints:

Lack of awareness about advanced personal mobility devices and unavailability of service centers is expected to hinder the market growth. Low access to rehabilitation centers in emerging economies is mainly found due to lack of proper transportation service for the people with disabilities.

Moreover, the number of rehabilitation centers is very low in emerging countries, which causes disabled people to travel for long distance to receive appropriate treatment.

Figure 2. Global Personal Mobility Devices Market Share (%), by End User, 2018 and 2026

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1662

Segment Information:

North America holds dominant position in the global personal mobility devices market, owing to the increasing geriatric population and growing patient population with limb impairment or disability. According to Centers for Disease Control and Prevention Report 2015, around 1.9 million people in the U.S. were living with limb loss due to diabetes, vascular diseases, infection, trauma, and cancer.

Moreover, launch of products, investment, and acquisition strategies by market players is expected to propel growth of the personal mobility devices market. For instance, in August 2017, Invacare Corporation announced the launch of Invacare TDX SP2 Power Wheelchair with LiNX Technology and Motion Concepts Ultra Low Maxx Positioning System.

Key Players

Major players operating in the global Personal Mobility Devices Market include Invacare Corporation, Pride Mobility Products Corporation, Drive Devilbiss Healthcare, Sunrise Medical (US) LLC, Permobil, Acorn Stairlifts Inc., Stannah International, Ottobock Healthcare, R&E Stricker Reha-Entwicklungen GmbH, Triride Srl, Klaxon Mobility GmbH, Alber GmbH, Spinergy, Inc., and Yamaha Motor Co., Ltd.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Fiber optics are thin, long strands of very pure glass, arranged in bundles that are used to translate light signals over long distances. Various medical instruments utilize fiber optics for several applications including laser signal delivery, illumination, and image transfer.

Market Drivers

MIS refers to a medical surgery, which performed through small incisions rather than large incisions. Since there is reduced blood loss, these surgical procedures are gaining major traction in hospitals and clinics worldwide. Furthermore, MIS offers shorter hospital stays, fewer complications, and low cost. Hence, these factors are expected to drive growth of the global medical fiber optics market during the forecast period.

The prevalence of gastrointestinal and digestive diseases has increased significantly in the recent past in both developed and emerging economies. According to the Centers for Disease Control and Prevention (CDC), in 2019, there were around 14.8 million adults in the U.S. diagnosed with ulcers. Medical fiber optics can be used in diagnosis and analysis of ulcers, which in turn, is expected to propel the global medical fiber optics market growth in the near future.

Statistics:

North America held dominant position in the global Medical Fiber Optics Market in 2019, accounting for 36.0% share in terms of value, followed by Europe, APAC, Latin America, and MEA respectively.

Figure 1: Global Medical Fiber Optics Market Share (%), in terms of Value, By Region, 2019

Market Restraints

Many medical professionals and patients are preferring non-invasive diagnostics and monitoring methods for obvious reasons. These methods include glucose concentration, hemodynamic monitoring, X-rays, EKG, ECG, etc. As a result of this, the demand for medical fiber optics has declined significantly. Therefore, these factors are expected to restrain growth of the market in the near future.

There still remains a major issue of integrating novel technology in healthcare industry that can help physicians to diagnose and monitor patients efficiently.

Moreover, solution providers offer various devices that are compatible with certain optical fibers due to technical specifications and requirements. Hence, these factors are expected to hamper the market growth over the forecast period.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1645

Market Opportunities

Key companies in the market are focused on research and development activities, in order to innovate novel products. For instance, in June 2015, Leoni introduced radiation-resistant multi-mode fibers for computer tomography applications. These fibers are IEC 60332-1-2 and IEC 60332-3-22 Cat. A compliant.

Key market players are focused on business and capacity expansion, in order to enhance the market presence. For instance, in March 2015, Schott AG expanded its Puravis glass optical fiber solutions by introducing rigid fiber rods for dental devices applications.

Figure 2: Global Medical Fiber Optics Market Value (US$ Mn), 2017 - 2027

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1645

Market Trends

North America Trends

Among regions, North America is expected to witness significant growth in the global medical fiber optics market during the forecast period. This is owing to high presence of major manufacturers across the U.S. Furthermore, technological advancements and rising foreign investment are expected to boost the regional market growth over the forecast period.

Europe Trends

Europe is expected to register a robust growth rate in the global medical fiber optics market over the forecast period. This is owing to strong industrial growth across the region. Furthermore, increasing surgical procedures in developed countries such as Germany, France, and the U.K. is expected to propel the regional market growth in the near future.

Competitive Section

Key players operating in the global Medical Fiber Optics Market Leoni AG, Sunoptic Technologies LLC, Gulf Fiberoptics, Inc., Integra LifeSciences Holdings Corporation, Coherent, Inc., Molex Incorporated, Fiberoptics Technology, Inc., Newport Corporation, and Schott AG.

Key Developments

Key market players are focused on product launches, in order to expand the product portfolio. For instance, in November 2019, Schott AG launched SCHOTT SingleEZ Guide plug-and-play illumination solution for single-use endoscopes.

Major market players are involved in product development, in order to gain a competitive edge in the market. For instance, in March 2019, Schott AG launched Autoclavable Solidur LEDs for use in dental and medical technology applications.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Medical tubes are intrinsic part of various medical devices, used extensively in catheters and cannulas’ manufacturing, drug delivery systems, dialysis, and intravenous tubing. Medical tubes are usually a small plastic tube, which are inserted into the patient’s body through mouth, nose, or any cut in skin to deliver oxygen, anesthesia, drugs, or any other fluid.

The global Medical Tubing Market size is estimated to be valued at US$ 6,921.1 million in 2018.

Global Medical Tubing Market Share (Value Terms), by Region, 2018                     

Market Drivers

Increasing prevalence of chronic diseases and life threatening diseases is expected to drastically increase demand for medical tubing devices, which are essentially required during surgery procedures. For instance, according to Centers for Disease Control and Prevention (CDC), 2017, around 610,000 people die of heart disease in the U.S. every year.

According to a report published by the Australian Government, Department of Health in 2017, it was estimated that 1 in every 2 Australians (50%) suffers from at least one type of chronic condition, such as arthritis, asthma, back pain, cancer, cardiovascular disease, chronic obstructive pulmonary disease, diabetes or mental health conditions. Thus, high prevalence of chronic diseases and life threatening diseases is expected to be one of the major factors driving growth of the global medical tubing market.

Request for the Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/1643

Market Opportunities:

Launches of advanced medical tubing solutions with latest technological features are expected to offer prominent growth opportunity for medical tubing manufacturers in the market.

For instance, in 2017, ART Medical Ltd., Israel-based startup, developed a novel sensor-based smart tube that enables healthcare professional to collect comprehensive patient data and reduces the risk of medical complications. This novel medical tube is able to gather the patient data such as feeding needs, saliva secretion, and urine output by using sensors embedded in the tubes.

Launches of such novel and smart medical tubing in future is enable to continue the technological advancement in the medical tubing, during the forecast period. 

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1643

Market Restraints:

Side effects related to materials used in manufacturing of medical tubing is expected to restrain the growth of market. For instance, in February 2017, U.S. Food and Drug Administration (FDA) pointed out that DEHP (di-2-ethylhexyl phthalate), which is used in PVC as a plasticizer (softener), may be absorbed into blood and body fluids, causing health problems.

In 2012, Kaiser Permanente, an American-managed care consortium, banned PVC tubing and bags, and adopted 100% PVC and DEHP (di-2-ethyl hexyl phthalate) free intravenous tubing. Hence, side effects related to medical tubing material is expected to restrain growth of the market.

Some of the key players operating in the Medical Tubing Market are

Compagnie de Saint-Gobain S.A., Teleflex Incorporated, Optinova Holding AB, Zeus Industrial Products, Inc., The Lubrizol Corporation, Nordson Corporation, Putnam Plastics Corporation, Raumedic AG, Tekni-Plex, Inc., and Smith Group plc.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Increasing interest in developing quick, cost-effective, and environmentally friendly sample preparation techniques, lead to develop new methods which will eventually minimize the extraction steps, reduce solvent consumption, and thereby automate the sample preparation system. Sample preparation is necessary to isolate the desired or targeted components from complex matrices, which most analytical instruments cannot handle the matrix directly. Automated sample preparation eliminates human error, low sample purity, and sample contamination, allowing consistent result at every time.

The global Sample Preparation Market was valued at US$ 5.7 billion in 2017.

Global Sample Preparation Market, By Product Type

Market Drivers

Increasing adoption of innovative technologies and high requirement for product development are propelling demand for automation in sample preparation instrument. Also, it lowers operator’s health and safety risks by reducing exposition to hazardous chemicals and biological laboratory samples.

Moreover, key players are focused on introducing innovative products in the sample preparation market, which is expected to drive growth of the market. For instance, in March 2018, Inlabtec AG, introduced TA12 Serial Diluter: a low cost, high productivity dilation system for quantifying live probiotic bacteria.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1594

Various government and private organizations are focusing on increasing R&D investment in clinical diagnostic, forensic, proteomics, and genomics research. Proper sample preparation is vital to obtain significant and accurate results. Moreover, increasing research and development (R&D) spending by various government and private organizations is expected to increase adoption of advanced sample preparation instrument in near future. In April 2018, DNA Script received US$ 5.5 million in funding from European Commission and French investment bank: Bpifrance. Funding is provided as a part of subsidies and refundable advances of European Commission’s Horizon 2020 European Innovation Council program and Bpifrance's innovation development programs.

Emerging markets such as Asia Pacific, Latin America, Middle East and Africa with their increasing population, high healthcare expenditure and their ability to file increasing numbers of patents in different research fields, will lead to drive sample preparation market, in these region. For instance, according to the World Intellectual Property Indicators 2017 report, Asia (64.6%) accounted to register highest percentage of patent applications for 2016, followed by North America (20.5%), Europe (11.3%), Latin America and the Caribbean (2%), Oceania (1.1%), and Africa (0.5%). According to the same source, in 2016, China registered highest number of patents (1,338,503 patent applications), with 21.5% annual growth.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1594

Market Restraints :

Expensive setup for sample preparation and shortage of skilled professionals to operate advanced sample preparation instruments may lead to hinder the sample preparation market, during the forecast period. Sample preparation can be complex when analyzing the drugs in biological matrices, which requires high skilled professionals to operate. In some of the primary steps of sample preparation such as drawing blood or excising tumor tissue and executing it into a plate or tube (from which it is accessible to the automated sample preparation system), requires a high level of skill.

Moreover, limitations of sample preparation system varies with instrument type and sample. In most of sample preparation process, samples are usually fluids.

Key players operating in the Sample Preparation Market include

F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Danaher Corporation, Qiagen N.V., PerkinElmer, Inc., Illumina, Inc. and Merck KGaA.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Hemostasis is a physiological processes, which maintains fluidity of blood by preventing blood loss from body. Hemostasis is characterized by clot formation by activating the natural coagulation cascade.

The global Hemostasis & Tissue Sealing Agents Market was valued at US$ 3,236.2 million in 2017 and is expected to witness a robust CAGR of 8.1% over the forecast period (2017–2025).

Figure 1. Global Hemostasis & Tissue Sealing Agents Market Value (US$ Mn), by Region, 2017

Market Drivers:

Factors such as increasing number of surgical procedures as well as rising number of road accidents are expected to significantly contribute to growth of the hemostasis and tissue sealing agents market. For instance, according to Health and Social Care Information Centre (HSCIC), surgery is one of the most important treatments offered by NHS care in the U.K., and accounted for 4.7 million admissions across multiple sectors in 2013-14.

Increasing incidence of road accidents has led to traumatic sport injuries is a major factor fueling demand for hemostats, thereby driving the market growth. According to the World Health Organization 2016, over 50% affected in road traffic accidents were admitted in the hospitals and underwent trauma surgeries.  

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1567

Key players in the market are focused on expansion of their presence through launch of new product lines in emerging economies. For instance, in March 2018, Baxter International, Inc. completed acquisition of two hemostat products from Mallinckrodt Plc and announced to widen its customer base through launch of RECOTHORM and PREVELEAK hemostat sealant in Japan.

Moreover, players are also focusing on offering innovative products, in order to enhance their market share. For instance, in January 2018, Ethicon LLC, a part of Johnson & Johnson Medical Devices Companies, introduced SURGICEL powdered absorbable hemostat that assists to combat disruptive bleeding on broad and oozing surfaces.

Market Restraint:

Lack of favorable reimbursement policies for failure of hemostats in blood loss control as well as increasing cost of surgical procedures is expected to hinder the market growth.

 Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1567

Segment Information:

In terms of region, North America is the dominant in the global hemostasis & tissue sealing agents market. This is attributed to rapid development and launch of novel tissue sealing compounds and products by key players in the market in the region. For instance, in March 2018, BodeVet, Inc., a blood-related products company, introduced StablePlate RX Canine as the world’s first injectable freeze dried platelet derived product used for the treatment of acute uncontrolled hemorrhage in bleeding patients

On the other hand, Asia Pacific is expected to exhibit high growth over the forecast period, owing to rising number of surgical procedures as a result of increasing medical tourism in emerging economies such as China, Singapore, and India.

Additionally, rising number of road accidents in Asia Pacific region leading to trauma admissions in emergency departments also contributes to the growth of the market in the region over the forecast period. According to the Ministry of Road Transport and Highways, Government of India, the total number of persons injured in road accidents in 2015 are 500,279. These are expected to aid in growth of the market.

Key players operating the global Hemostasis & Tissue Sealing Agents Market include

Cryolife, Inc. Baxter International, Inc., Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc., Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc, and others.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Molecular diagnostics tests are used for detecting disturbance between specific sequences in DNA or RNA, which may be associated with disease. The disturbance between a single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others factors lead to various diseases. Disease that are diagnosed by using molecular diagnostic test includes infectious diseases, oncology, virology, and STDs.

The Molecular Diagnostics Market is estimated to be valued at US$8,623.2 Mn in 2017.

Molecular Diagnostics Market Share, By Product Type (%)

Market Drivers:

Application of biomarkers in molecular diagnostic is increasing, due to advantages of biomarkers such as aiding in early detection of specific diseases. For instance, biomarkers are used in detection of ABO haemolytic diseases in new born, Huntington's disease and hereditary haemochromatosis, and cystic fibrosis.

Biomarkers are also used in detection of disorders related to chromosome structure such as Turner syndrome, Down syndrome, patau syndrome, and Edwards’s syndrome. Furthermore, biomarker also have wide application in therapeutic areas, which includes neurological diseases, metabolic disorders, immune deregulation, and oncology.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1545

Increasing research and development for identification of biomarkers have led to development of new molecular diagnostic tests, which is expected to foster growth of the molecular diagnostics market. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkes, Inc. for the first diagnostic blood test, for traumatic brain injury, Banyan BTI. Such innovations for various disease indication is expected to drive growth of the molecular diagnostics market in the near future.

Regional insights

North America accounts for the largest share in the global molecular diagnostics market and this is attributed to increasing adoption of precision medicine and growing prevalence of cancer. 

According to a National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024, in turn increasing the demand of the molecular diagnostics market in the near future.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1545

Key Development:

Key players in the market are involved in new product launches to cater to increasing demand for molecular diagnostic. For instance, in August 2016 Abbott Laboratories introduced Alinity, a next generation system, used for immunoassay, clinical chemistry, point-of-care, hematology, blood and plasma screening, and molecular diagnostics.

Some of the other key players in the global Molecular Diagnostics Market include 

Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, and Beckman Coulter, Inc.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

ePharmacy, also known as electronic pharmacy or Internet pharmacy, is an online retail platform that acts as an intermediary between customers and the vendors to enable the sale of medicine. 

The global ePharmacy Market is estimated to account for US$ 81.6 Bn in terms of value in 2020 and is estimated to reach US$ 244.0 Bn by the end of 2027.

Market Drivers

Increasing adoption of Internet is expected to propel growth of the global ePharmacy market over the forecast period. For instance, according to Pew Research Center, the percentage of households with broadband connection in the U.S. increased from 68% in January 2018 to 77% in February 2019.

Increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.     

Statistics:

North America held dominant position in the global ePharmacy Market in 2019, accounting for 35.9% share in terms of value, followed by Europe and Asia Pacific, respectively

Request for the Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/1544

Figure 1. Global ePharmacy Market Share (%), by Region, 2019

Market Opportunities  

Large untapped markets in Latin America are expected to offer lucrative growth opportunities for players in the market. Presently, Latin America and Middle East and Africa are the least-tapped markets for ePharmacy, owing to high presence of physical pharmacy stores and underdeveloped healthcare infrastructure in most countries in these regions.

Moreover, increasing disposable income in Asia Pacific is also expected to display lucrative growth opportunity for players in the market. For instance, according to The Ministry of Statistics and Program Implementation, Government of India, disposable personal income in India increased to US$ 2,699,821.02 Million in 2019 from US$ 2,517,856.54 Million in 2018.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1544

Figure 2. Global ePharmacy Market Value (US$ Bn), and Y-o-Y Growth (%), 2019-2027

Market Trends

Major players in the market are focused on offering various digital services. For instance, in February 2020, Ro, an ePharmacy, launched Health Guide, a new medical handbook for the internet.

Major players in the market are also focused on investing in shop-in-shop pharmacies. For instance, in October 2019, Zur Rose Group AG partnered with Migros, a Switzerland-based retail company, to start the first shop-in-shop pharmacy in Switzerland.

Major players operating in the global ePharmacy Market include, 

CVS Caremark, Banner Health, DocMorris NV, Ro, Zur Rose Group AG, Right ePharmacy, PlanetRx.com.Inc., Lloyds Pharmacy Ltd., Dr. Fox Pharmacy, eDrugstore.MD, MediSave, Walgreen Co, and Rowlands Pharmacy.

Key Developments    

Major players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in December 2019, DocMorris NV partnered with KRY International AB, a healthcare company, under which electronic prescription issued through KRY app can be redeemed at the DocMorris pharmacy or an on-site pharmacy.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in January 2019, Zur Rose Group AG announced the acquisition of e-commerce activities of medpex, an online pharmacy, which include, Comventure GmbH, Visionrunner GmbH, medpex wholesale GmbH, and Apotheke esando B.V.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Biomarkers are the molecules used for diagnosis of diseases as these indicate normal or abnormal process in the body. Biomarkers can be any molecules such as DNA (genes), proteins or hormones that indicate about the health and can be classified on basis of different parameters, which includes characteristics such as imaging biomarkers or molecular biomarkers.

The Biomarkers Market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025).

The Global Biomarkers Market Value (US $ Mn), By Region (2017)

Market Drivers:

Increasing application and awareness about biomarker tests is expected to be a major factor for growth of the market. Biomarkers are also applied to a wide variety of therapeutic areas, which include neurological diseases, metabolic disorders, immune deregulation and oncology to treat various disease such as TMI, cancer, Alzheimer diagnosis. Biomarkers are also used to detect ABO haemolytic disease of new born, Huntington disease, and hereditary haemochromatosis, and cystic fibrosis.

Furthermore, biomarkers are used to detect disorder related to chromosome structure such as, Turner syndrome, Down syndrome, patau syndrome, Edwards’s syndrome, and others, which has led to increasing demand for biomarkers.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1530

North America accounts for the largest share in the global biomarkers market and this is attributed to adoption of precision medicine and growing prevalence of cancer in the region. According to the National Cancer Institute, 2016, it was estimated that 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from cancer disease. The number of people suffering from cancer is expected to rise to 19 million by 2024, which supports increasing demand for precision medicine.

Furthermore, the U.S. government in 2015 announced the launch of Precision Medicine Initiative that aimed to revolutionize the treatment to improve health, as precision medicine is an innovative approach to offer tailored treatment. Precision Medicine Initiative have led to development of novel drugs and new treatments, tailored for specific characteristic such as person’s genetic makeup or genetic profile of an individual tumor that helps to transform the way of treatment. This also favors growth of the biomarkers market in the near future. As for the development of precision medicine, it is essential to identify biomarkers.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1530

Key Development:

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform.

Some of the other key players in Biomarkers Market include

Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Immune repertoire sequencing is extensively used in biomarker discovery to improve the success rate and cost-effectiveness of rational drug development. For instance, in November, 2017, the Center for Commercialization of Cancer Immunotherapy (C3i) started offering T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit in Canada..

The global Immune Repertoire Sequencing Market size was valued at US$ 114.3 million in 2017.

Global Immune Repertoire Sequencing Market Share (%) Analysis, By Product Type, 2017

Market Drivers:

Increasing demand for personalized medicine, in turn, is expected to aid the immune repertoire sequencing market growth, as personalized medicine uses an individual’s genetic profile to guide decisions made in regard to the diagnosis, prevention, and treatment of diseases

Increasing research and development and launches of novel products by key players are expected to be the major driving force for global immune repertoire sequencing market growth in the near future. For instance, in 2017, ArcherDX, Inc. launched Archer Immunoverse B Cell Receptor (BCR) assays to characterize the human B cell repertoire.

According to a study published by Cold Spring Harbor Laboratory, in 2017, researchers from Stanford University applied immune repertoire sequencing to identify disease-related signatures in the immune systems of patients with systemic sclerosis-related pulmonary hypertension (SSc-PAH), a rare chronic autoimmune disease that affects the connective tissue. Therefore, increasing research on immune repertoire sequencing is expected to create a favorable environment for immune repertoire sequencing market growth in the near future.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1517

Market Restraints

Challenges in immune repertoire sequencing include distinguishing biological variations from the errors and the bias introduced in different steps. Conventional and novel bioinformatics techniques such as high throughput screening, Haystack Heuristic, and others are not up to the mark due to unsatisfactory scalability and sensitivity, and limitation in providing sufficient and accurate data.

Moreover, the differences of data generation and processing in different laboratories along with the challenges in immune repertoire sequencing system are some key factors, which may hamper growth of the immune repertoire sequencing market size.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1517

Market Regional Insights

North America is expected to hold a dominant position in the global immune repertoire sequencing market during the forecast period, owing to high presence of key industry players in the region (including Illumina Inc., Thermo Fisher Scientific, Pacific Biosciences, and CD Genomics). These players are increasingly focusing on development of novel technologies for immune repertoire sequencing.

The market in Europe is expected to gain momentum during the forecast period, owing to rise in funding by the government bodies to support international innovative projects and marketable innovative products, processes, and services, in order to cater unmet medical need. In July 2018, Eurostars (a joint program between EUREKA and the European Commission) granted US$ 495,000 to OSE Immunotherapeutic SA’s project entitled: ‘Treatment Response Monitoring for Cancer Immunotherapies Using Immune Repertoire Analysis’.

Global Immune Repertoire Sequencing Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2026

Key players operating in the global Immune Repertoire Sequencing Market include

Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Recombinant proteins are used in development of novel therapies for severe chronic diseases such as cancer and other rare diseases. Recombinant protein production requires a special technique known as recombinant DNA (rDNA) technology.

The global Recombinant Protein Market was valued at US$ 347.2 million in 2016.

Market Drivers:

Biopharmaceutical organizations are focusing on research and development of novel biosimilars for life threatening diseases such as cardiovascular diseases, cancer, metabolic disorders such as diabetes, and certain rare conditions such as hemophilia.

According to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S.

Rare disease medical space holds potential as there is relatively low competition. This is owing to less understanding of the disease progression pathways and entities. Therefore, companies could focus on R&D for development of biologics and subsequently biosimilars in this space. Demand for biosimilars is increasing significantly, owing to high prices of biologics, in turn leading to high demand for recombinant protein.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1516

Figure 1. Global Recombinant Protein Market Share, by Application (%) 2017 and 2025

Advancement in technologies in various areas associated with or facilitating recombinant protein production have supported growth of recombinant protein market. For instance, development of alternative expression technologies such as mammalian cell expression, baculovirus expression, and E.coli expression, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized recombinant protein processes.

Moreover, advancements in bioreactor systems have improved the product’s output within shorter time. According to National Centre for Biotechnology Information (NCBI), in 2014, about 65.6% of clinical scale manufacturers and 42% of commercial manufacturers adopted single use bioreactor for improvement in their bioprocessing.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1516

Market Restraints:

Factors such as complex manufacturing process, high costs, and requirement of high quality of these products (responsible for high costs) are expected to hinder growth of the market over the forecast period.

Some major players operating in the Recombinant Protein Market include

Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Neurological disorder diagnostics tools are medical devices that are used for diagnosing various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. 

The global Neurological Disorder Diagnostics Market size is expected to be valued at US$ 12,162.6 million in 2019 and is expected to exhibit a CAGR of 7.6% over the forecast period (2019–2027).

Figure 1. Global Neurological Disorder Diagnostics Market Value (US$ Mn), by Region, 2019

Market Drivers:

In the recent past, several key players in the market have received approval for launching novel diagnostic tools. Moreover, approval and launch of such novel tools in the market is expected to create lucrative environment for the global neurological disorder diagnostics market growth over the forecast period. For instance, in April 2018, Canon Medical Systems received 510 (k) clearance from the U.S. Food and Drug Administration for its new Aquilion Precision (CT) scanner. Aquilion Precision is an ultra-high resolution CT system (UHR CT).

Moreover, in March 2018, Koninklijke Philips N.V. launched its new 3-tesla MRI scanner, Elition 3.0T. This new MRI scanner reduces scanning time by 50%, which is expected to enhance patient experience. Furthermore, in January 2019, Canon Medical Systems Corporation launched Aquilion Start CT system with 16 and 32 slice configurations suitable for institutions aspiring to make diagnostic CT imaging more accessible and affordable.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1867

Market Restraint:

High cost of diagnostic tools such as MRI machines and CT scan is a major factor, which is expected to hinder growth of global neurological disorder diagnostics market in emerging economies such as India, and China. According to American Health Imaging, price of a magnetic resonance imaging (MRI) devices starts from US$ 150,000, and a high end device costs more than US$ 1 million. Such high cost devices are only adopted by big hospitals and diagnostic laboratories.

Figure 2. Global Neurological Disorder Diagnostics Market Share (%), by Disease Indication

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1867

Market Opportunities:

Strategic collaborations among key players are expected to fuel growth of the global neurological disorder diagnosis market over the forecast period. For instance, in March 2018, Canon Medical Systems, Kumamoto University, and University of Bordeaux entered into a collaborative research for the development of deep learning technology in magnetic resonance imaging.

Moreover, in 2017, Singapore-based National Neuroscience Institute and Nanyang Technological University (NTU Singapore) collaborated to develop novel and innovative technologies for better diagnosis and treatment of patients with neurological conditions such as Parkinson’s disease, and brain injuries.

Key Players

Major players operating in the global Neurological Disorder Diagnostics Market include Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Alopecia is the condition described for excessive hair damage or hair loss. Alopecia treatment plays a major role in advanced healthcare, as it aids in prevention of hair fall and regrowth of hair. 

The global Alopecia Treatment Market size was valued at US$ 7,325.0 million in 2017.

Figure 1. Global Alopecia Treatment Market Value (US$ Mn), by Region, 2018

Market Drivers:

Rising product launch and robust pipelines are expected to drive the global alopecia treatment market. For instance, in November 2018, Fidia Pharma launched Trinov hair growth lotion for hair growth in Italy. Furthermore, in September 2018, Eli Lilly and Company initiated phase 2 clinical trial to assess the safety and efficacy of Baricitinib drug in treating patients with alopecia areata. The study is estimated to complete in August 2022.

Rising initiatives such as crowdfunding campaigns and increasing collaboration by the market players is expected to bolster the market growth. For instance, in 2018, HairClone, a U.K. based company working on cellular hair restoration therapies, launched its public crowdfunding campaign. The company collaborated with Capital Cell, a crowdfunding company. Similarly, in May 2013, RepliCel Life Sciences Inc. and Shiseido Company, Limited announced collaboration and technology development transfer framework agreement for RepliCel’s RCH-01 hair regeneration technology.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1847

Increasing acquisition strategies in the region by the market players are major factor expected to propel the market growth. For instance, in August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., which expanded Aclaris’ inflammation and immunology pipeline with the addition of Confluence’s lead product candidates CDD-450, topical Janus kinase inhibitors, and IL2-inducible T-cell kinase inhibitor programs.

Figure 2. Global Alopecia Treatment Market Share (%), by Disease Type, 2018 and 2026                 

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1847

Segment Information

North America holds dominant position in the global alopecia treatment market, owing to increasing prevalence of Alopecia Areata and active research activities by market players. For instance, according to the National Alopecia Areata Foundation (NAAF), 2017, alopecia areata affects around 6.8 million people in the U.S. with a lifetime risk of 2.1%. Moreover, the NAAF is focused on broadening research efforts through two committees, including the Basic Research Advisory Council (BRAC), and the Clinical Research Advisory Council (CRAC), in order to advance the Alopecia Areata Treatment Development Program

Moreover, collaboration of market players with regulatory authorities as well as other government organizations is further expected to support growth of the North America alopecia treatment market over the forecast period. For instance in April, 2019, Precision Therapeutics Inc., Helomics, and the National Alopecia Areata Foundation (NAAF), entered into an agreement to treat people affected by an autoimmune skin disease called alopecia areata. The agreement was intended to provide a next-generation patient registry to drive research on new treatments for people with this disease.

Key Players

Major players operating in the global Alopecia Treatment Market include Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Scoliosis is a medical condition that causes an abnormal curve of the backbone or spine. It is mostly diagnosed in early adolescence or in childhood.        

The global Scoliosis Management Market was valued at US$ 2,267.8 Mn in 2017.

Global Scoliosis Management Market Share (%), By Spinal Location, 2018 & 2026

Market Drivers:

The growth of scoliosis management market is majorly driven by the increasing prevalence of scoliosis, worldwide. For instance, according to the American Association of Neurological Surgeons (AANS): 2007, around 2–3% of the population is suffering from scoliosis in the U.S. alone with estimates of six to nine million people. Moreover, according to the same source, every year, around 600,000 patients visit private facilities, over 30,000 adolescents use braces, and around 38,000 patients have undergone spinal fusion surgeries in the U.S.

According to the AANS, primary age of onset for scoliosis is 10-15 years old, occurring equally among both genders. Females are eight times more likely to progress to a curve magnitude that requires treatment.

According to an article published in the Journal of Back and Musculoskeletal Rehabilitation in 2014, scoliosis occurs in around 3% of people globally, most commonly among girls. Moreover, increasing government and private intervention in the field of research and clinical studies have also propelled scoliosis management market growth significantly.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1842

Global Scoliosis Management Market Share (%), By Demographics, 2018 & 2026

Market players in this market are engaged in developing new technologies for scoliosis management by adopting organic and inorganic growth strategies. For instance, in 2015, researchers from the Xiao Feng Spinal Deformity Studio and National Rehabilitation Aids Research Center in Beijing created country's first customized 3D printed back brace for the treatment of scoliosis.

Furthermore, market players are engaged in developing new technologies, in order to hold dominant position in the market. For instance, in September 2018, NuVasive, Inc. launched MAGEC X, the latest product within the MAGEC pediatric portfolio to address early-onset scoliosis (EOS) in the U.K. MAGEC X offers 68% improved fatigue-strength performance over the conventional 4.5mm option.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1842

Segment Information:

Among region, North America is expected to be the most lucrative region in the scoliosis management market over the forecast period due to presence of prominent market players in this market and their increasing engagement in adopting organic and inorganic growth strategies. For instance, Alphatec Spine Inc., a California-based medical device company engaged in designing, developing, manufacturing, and marketing of spinal fusion technology products and solutions, launched its new Arsenal Deformity Adolescent Idiopathic Scoliosis (AIS) System in the U.S.

Moreover, increasing number of scoliosis surgery procedures conducted in the U.S. supports growth of the market. For instance, according to the World Journal of Orthopedics: 2015, around 29,000 scoliosis surgeries are performed on adolescents annually in the U.S.

Key players operating in the Scoliosis Management Market include

Boston Orthotics & Prosthetics, Aspen Medical Products, Lawall Prosthetics and Orthotics, Horton’s Orthotics & Prosthetics, Spinal Technology Inc., Ortholutions GmbH & Co. KG, Ossur Hf, Charleston Bending Brace, UNYQ, and Pro-Tech Orthopedics.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Peptides are selective and efficacious signaling molecules that bind to specific cell surface receptors to trigger intracellular effects.

The global Peptide Therapeutics Market is estimated to account for US$ 23,319.3 Mn in terms of value and is expected to reach US$ 57,166.5 Mn by the end of 2027.

Market Drivers

Increasing prevalence of metabolic diseases and cardiovascular disorders (CVDs) is expected to boost growth of the global peptide therapeutics market over the forecast period.

Moreover, increasing healthcare expenditure is also expected to aid in growth of the market. For instance, according to the Centers for Medicare & Medicaid Services (CMS), health spending in the U.S. is projected to grow at an average rate of 5.5% per year for 2018-27 and to reach nearly US$ 6.0 trillion by 2027.

Statistics:

North America region held dominant position in the global peptide therapeutics market in 2018, accounting for 42.1% share in terms of value, followed by Europe.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1837

Market Opportunities

R&D of new peptides is expected to offer lucrative growth opportunities for players in the market. For instance, in December 2019, CohBar, Inc. announced new preclinical data that confirmed the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis (IPF).

Moreover, R&D in microbiome research is also expected to boost growth of the peptide therapeutics market. In January 2020, researchers from The Chaim Sheba Medical Center, Israel, reported that high fructose consumption induced metabolic changes and dysbiosis in rats and that metabolic changes are probably independent of a specific microbiome profile. 

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1837

Market Trends

The market is witnessing increasing adoption of new platforms that develop next-generation protein or peptide therapeutics. For instance, in January 2020, Xenetic Biosciences, Inc. announced publication of the data from the completed Phase 1/2 clinical study of SHP656 ("PSA-recombinant Factor VIII", "PSA-rFVIII") in the journal Haemophilia.

The market is also witnessing increasing M&A activities. For instance, in January 2020, Almirall, S.A. acquired Bioniz Therapeutics Inc., a clinical stage biopharmaceutical company that develops first-in-class peptide treatments for immuno-inflammatory diseases.

Major players operating in the global Peptide Therapeutics Market include,

AstraZeneca plc., Bachem Holding AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical Industries Ltd.

Key Developments

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in October 2019, PolyPeptide Group collaborated with the Green Chemistry and Enabling Technologies Team of IBMM (Institut des Biomolécules Max Mousseron), for R&D greener solutions to produce synthetic peptides.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in July 2019, Xenetic Biosciences, Inc. completed acquisition of the novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” designed to use screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor of malignant tumor cells.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Naloxone is a medication which is mainly used to reverse opioid overdose such as morphine and heroine. Naloxone is an opioid antagonist and the U.S. Food and Drug Administration (FDA) list it under prescription drugs, however some countries such as Italy and Australia have rescheduled it as an over-the-counter (OTC) medication.

The global Naloxone Market size was valued at US$ 310.2 Mn in 2017.

Market Drivers:

Increasing launches and approval of novel naloxone products by various regulatory bodies is expected to be a major factor aiding in growth of the market over the forecast period. For instance, in January 2017, the U.S. Food and Drug Administration (FDA) approved Adapt Pharma Inc.’s NARCAN Nasal Spray 2 mg formulation for emergency treatment of known or suspected opioid overdose. In September 2017, Mundipharma International Limited received approval from European Medicines Agency (EMA) for its product (intranasal naloxone 1.8 mg) to use in emergency reversal of opioid overdose.

Figure 1. Global Naloxone Market Share (%), By Strength, 2018–2026

Increasing cases of opioid overdose is expected to increase demand for naloxone products during emergency treatments which in turn will positively drive the global naloxone market growth. For instance, According to the data published by National Institute on Drug Abuse, 2018, in the U.S., everyday over 115 people die due to opioid overdosing. According to same source, in the U.S. opioid overdose increased by 30% from July 2016 through September 2017 in 52 areas in 45 states.

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1804

Figure 2. Global Naloxone Market Share (%), By Region, 2026

Market Opportunities:

Reimbursement scenario for drugs play a major role in adoption of high cost products in developed regions such as North America and Europe. Therefore, favorable reimbursements for naloxone products is expected to support the adoption of these products. Currently, most types of insurance cover and reimburse for naloxone administered directly in a medical setting.

Furthermore, some states in the U.S. have started covering take-home naloxone. Hence, adoption of take-home naloxone is expected to increase in the near future. For instance, in New York State from January 2014, the state’s Medicaid program began to cover the intramuscular formulation of take?home naloxone.

Segement Information:

North America naloxone market is expected to a hold dominant position over the forecast period due to the presence of novel naloxone products such as Narcan nasal spray and EVZIO (naloxone hydrochloride injection), which is still not present in any other region. 

Furthermore, initiatives taken by various companies and organizations to increase access of naloxone is expected to fuel the market growth. For instance, in February 2018, Loyola Medicine and the Cook County Department of Homeland Security and Emergency Management collaborated, where Loyola Medicine trained police officials to use Narcan in case of opioids overdose.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1804

Regulatory Scenario

In Europe, many countries allow take-home naloxone due to high rate of opioid overdose in this region. Currently, take-home naloxone programs exists in seven European countries— Denmark, Estonia, Germany, Italy, Norway, Spain, and the U.K. (EMCDDA, 2015c).

According to the data published by Regulatory Affairs Professional Society, naloxone is still not approved by the U.S. FDA as an over-the-counter (OTC) drug. However, some organizations such as Walgreens pharmacies are providing naloxone products over-the-counter in over 5,800 of its 8,200 stores to increase the access of naloxone.

Key players operating in the Naloxone Market include

Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702

Summary:

Breast implants are medical devices that are used to augment the size of the breasts, either for cosmetic or reconstruction purposes, following mastectomy or to correct a congenital abnormality. The process is called breast augmentation and involves use of breast implants and fat, called as fat transfer breast augmentation, in order to enhance and improve the size of the breasts.

Statistics:

Asia Pacific Breast Implants Market is estimated to account for US$ 329.5 Mn in terms of value by the end of 2027.

Market Drivers

Increasing prevalence of breast cancer is expected to propel growth of Asia Pacific breast implants market over the forecast period. For instance, according to the Union Health Ministry, Government of India, 2018 data, the prevalence of breast cancer is 25.8 per 100,000 women and the mortality rate for the disease is 12.7 per 100,000 women. Moreover, around 17, 97,900 women in India may suffer from breast cancer by 2020.

High preference for highly cohesive silicone breast implants is also expected to aid in growth of the market. Silicone breast implants have high strength silicone gel that is textured with silicone shell. Such implants are thicker and contain more cohesive silicone gel, which eliminates the probability of filler leakage into the body.

Figure 1. Asia Pacific Breast Implants Market Share (%), by Region, 2019

Request for the Sample copy @  https://www.coherentmarketinsights.com/insight/request-sample/1806

Market Restraints

Breast implants may lead to rare type of cancers, which is expected to hinder growth of the market. According to the U.S. FDA, breast implants can lead to anaplastic large cell lymphoma, a rare type of fast-growing non-Hodgkin lymphoma.

Moreover, high cost of breast augmentation is also expected to hamper growth of the market. For instance, in India, the total cost of breast augmentation (including cost of implants and cost of surgery) is around US$ 2,800.

Market Opportunities 

Introduction of lightweight breast implants is expected to offer lucrative growth opportunities for players in the market. Such implants can be developed using cohesive gel filler.

Moreover, use of 3D printing molds in developing prosthetic breasts is also expected to aid in growth of the market. For instance, New Zealand-based myReflection uses 3D scanning and 3D printing molds to develop customized prosthetic breasts for cancer patients who have received a mastectomy.

Request for the PDF Brochure @  https://www.coherentmarketinsights.com/insight/request-pdf/1806

Market Trends

Saline and silicone implants are the most used of implants in the market. However, teardrop or gummy bear implants are gaining rapid preference, owing to increasing preference for natural looking breasts.

The demand for fat transfer breast augmentation is high in the recent times. This is owing to wide perception among women that individual body fat offers a more natural look and feel; and less invasive nature of the procedure.

Major players operating in Asia Pacific Breast Implants Market include,

Allergan, Plc (Actavis Plc), Mentor Worldwide LLC. (Johnson & Johnson Services, Inc.), GC Aesthetics plc, Sientra, Inc., Groupe Sebbin SAS, Polytech Health & Aesthetics GmbH (Deutsche Beteiligungs AG), Establishment Labs S.A., CollPlant Holdings Ltd., HansBiomed Co., Ltd., Cereplas, and PS Technology Development Limited.

About Us

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt.Ltd.

Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1–206–701–6702